Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 610-945-6 | CAS number: 53037-34-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- September 11, 2012 - December 12, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- Oligomerisation reaction products of glyoxal and urea.
- EC Number:
- 610-945-6
- Cas Number:
- 53037-34-6
- Molecular formula:
- Not applicable (a generic molecular formula cannot be provided for this specific UVCB substance).
- IUPAC Name:
- Oligomerisation reaction products of glyoxal and urea.
- Details on test material:
- - Name of test material (as cited in study report): NOPCOTE 1661
- Physical state: Clear, light yellow solution
- Analytical purity: 46% in water solution.
- Lot/batch No.: 79389
- Expiration date of the lot/batch: 11 January 2013
- Storage condition of test material: Room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld.- Age at study initiation: Young healthy adult rats, approximately 8-9 weeks old.- Weight at study initiation: 171 - 190 g.- Fasting period before study: The night before treatment the animals will be fasted. - Housing: 3 animals/cage.- Diet (e.g. ad libitum): Ad libitum.- Water (e.g. ad libitum): Ad libitum.- Acclimation period: 5-6 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 19.9 – 24.1°C- Humidity (%): 30 - 52 %.- Air changes (per hr): 15-20 air exchanges/hour .- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- (distilled)
- Details on oral exposure:
- VEHICLE:- Amount of vehicle (if gavage): 200 mg/mL- Lot/batch no. (if required): 3450611MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bwDOSAGE PREPARATION (if unusual): The test item was freshly formulated at a concentration of 200 mg/mL in the vehicle. The formulation container was stirred continuously up to finishing the treatment. The purity factor was 2.18, therefore the dose to be adjusted was 2000 x 2.18 mg/kg bw prepared in distilled water at a dose volume of 10 ml/kg bw. With this the dose level was 2000 mg/kg bw referring to the dry component (46%) of the test item.CLASS METHOD (if applicable)- Rationale for the selection of the starting dose: In the lack of any preliminary toxicological information, 2000 mg/kg bw was selected to be the starting dose.
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3 females rats per group (group 1 and confirmatory group 2).
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days.- Frequency of observations and weighing: Clinical observations were performed on all animals at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Body weight was measured on Days -1, 0 and 7 and Day 14 before necropsy.- Necropsy of survivors performed: Yes, all animals were subjected to a necropsy and a macroscopic examination.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Treatment did not cause mortality.
- Clinical signs:
- other: Treatment caused decreased activity, hunched back and piloerection.
- Gross pathology:
- Treatment was not associated with any test item related gross findings.
Any other information on results incl. tables
Dose level: 2000 mg/kg bw, Treatment on day 0. Sex: Female.
Cage No. | Animal number | Observations | Observation days | Frecuency | |||||||||||
0 | 1 | 2 | 3 | 4 | 5 | 6-14 | |||||||||
30’ | 1h | 2h | 3h | 4h | 6h | ||||||||||
1 | 8156 | Symptom Free | - | - | - | - | - | - | - | + | + | + | + | + | 13/20 |
Activity decreased | - | - | - | 1 | 1 | - | - | - | - | - | - | - | 2/20 | ||
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | + | + | + | + | + | - | - | - | - | - | 5/20 | ||
8157 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Activity decreased | - | - | - | 1 | 1 | - | - | - | - | - | - | - | 2/20 | ||
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | + | + | + | - | - | - | - | - | - | - | 3/20 | ||
8158 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Activity decreased | - | - | - | 1 | - | - | - | - | - | - | - | - | 1/20 | ||
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | + | + | + | - | - | - | - | - | - | - | 3/20 | ||
2 | 8159 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 |
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | - | + | + | - | - | - | - | - | - | - | 2/20 | ||
8160 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | - | + | + | - | - | - | - | - | - | - | 2/20 | ||
8161 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | - | + | + | - | - | - | - | - | - | - | 2/20 |
Remarks:
+ = present - = absent
h = hour (s) ‘ = minute
Frequency of observation = number of occurrence of observation / total number of observations
Severities: 1 = Slight/Small/Few; 2 = Moderate/Medium; 3 = Marked/Large/Many
Table 2. Body weight data.
Dose level: 2000 mg/kg bw, Treatment on day 0. Sex: Female.
Cage No. | Animal number | Body weight (g) Days | Body Weight Gain (g) | ||||||
-1 | 0 | 7 | 14 | -1 - 0 | 0 - 7 | 7 - 14 | -1 - 14 | ||
1 | 8156 | 191 | 181 | 203 | 224 | -10 | 22 | 21 | 33 |
8157 | 200 | 184 | 224 | 252 | -16 | 40 | 28 | 52 | |
8158 | 198 | 187 | 217 | 229 | -11 | 30 | 12 | 31 | |
2 | 8159 | 185 | 171 | 198 | 205 | -14 | 27 | 7 | 20 |
8160 | 195 | 189 | 218 | 226 | -6 | 29 | 8 | 31 | |
8161 | 199 | 190 | 221 | 238 | -9 | 31 | 17 | 39 | |
Mean: | 194.7 | 183.7 | 213.5 | 229.0 | -11.0 | 29.8 | 15.5 | 34.3 | |
Standard deviation: | 5.8 | 7.0 | 10.5 | 15.6 | 3.6 | 5.9 | 8.1 | 10.6 |
Table 3. Necropsy findings.
Dose level: 2000 mg/kg bw, Treatment on day 0. Sex: Female.
Cage No. | Animal number | Necropsy Day | External Observations | Internal Observations | Organ/Tisuue |
1 | 8156 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable |
8157 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable | |
8158 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable | |
2 | 8159 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable |
8160 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable | |
8161 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable |
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral LD50 value of the test substance was >2000 mg/kg bw in female rats.
- Executive summary:
The single-dose oral toxicity was performed according to OECD 423 Guideline and EU B.1tris Method (acute toxic class method) in female CRL: (WI) rats. Two groups (one confirmatory group) of three rats were exposed by single oral treatment to 2000 mg/kg bw. Mortality, clinical observations and body weight were analyzed for 14 days after exposure. In day 14, necropsy was performed and all animals were subjected to a necropsy and a macroscopic examination. No effects on mortality, body weight and macroscopic findings were observed. Treatment caused decreased activity, hunched back and piloerection. Under the conditions of this study, the acute oral LD50 was determined to be greater than 2000 mg/kg bw in female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.